Weight Loss ยท Daily oral tablet
Foundayo
Foundayo is an oral form of tirzepatide, a dual GIP/GLP-1 medication from Eli Lilly, for patients who want tirzepatide's effect without a weekly injection.
Already know this is what you want? The second option books the appointment straight away. Not sure yet? See the labs first.
Your consult is free. We will not prescribe this, or anything, before a clinician has spoken with you. Final cost depends on the form and dose prescribed.
Mechanism
Two gut hormones, one tablet.
Tirzepatide, the active ingredient in Foundayo, acts on two hormone receptors, GLP-1 and GIP, rather than one. Together they slow digestion, reduce appetite and improve how the body responds to insulin, which is why dual-acting agents often outperform single-pathway GLP-1 medications on average weight loss.
Foundayo delivers tirzepatide as a daily tablet rather than a weekly injection, for patients who prefer not to inject or want to avoid needles.
Your clinician determines your starting dose and adjusts it over time, following the same gradual escalation approach used for the injectable version, Zepbound, to minimize nausea and other gastrointestinal side effects.
Pricing
How the cost breaks down.
Medication is paid separately to LillyDirect and shipped directly to you. Foundayo pricing and eligibility are determined by Eli Lilly and may change at any time.
Safety and eligibility
Your consult and labs screen for all of the following.
- Not suitable for everyone, dual GIP/GLP-1 medications are not appropriate for patients with a personal or family history of certain thyroid cancers or MEN 2, among other exclusions your clinician will screen for.
- Strict dosing instructions, follow the specific food and liquid timing instructions provided with oral tirzepatide for proper absorption.
- Common side effects, include nausea, vomiting, diarrhea, constipation and decreased appetite, especially during dose increases.
- Live visit required, prescribed only after a live visit with a licensed clinician.
FAQ
Foundayo questions.
Both contain tirzepatide from Eli Lilly; Foundayo is the oral tablet form, Zepbound is the weekly injection.
GIP and GLP-1 work on complementary pathways for appetite and insulin response, which is why dual-acting agents often show larger average weight loss than single-pathway GLP-1s in trials.
Yes, discuss it with your clinician, switching is common if one form isn't the right fit.
Your program fee covers your clinician and ongoing care; the medication itself is billed and shipped directly by LillyDirect at Lilly's pricing.
We will not prescribe before we understand you.
Book a one-to-one consult with the clinical team. We talk through your goals, order the bloodwork that matters, and build a plan from what we find.